A5071099056- Diet and metabolism studies
- Pharmacological Effects and Toxicity Studies
- Electrolyte and hormonal disorders
- Cancer Cells and Metastasis
- 3D Printing in Biomedical Research
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Religion, Spirituality, and Psychology
- Alcoholism and Thiamine Deficiency
- Cannabis and Cannabinoid Research
- Monoclonal and Polyclonal Antibodies Research
- Neurological and metabolic disorders
- Cancer Immunotherapy and Biomarkers
- Vitamin C and Antioxidants Research
- Substance Abuse Treatment and Outcomes
- T-cell and B-cell Immunology
- Single-cell and spatial transcriptomics
Boston College
2020-2021
Beth Israel Deaconess Medical Center
2018-2021
Harvard University
2020-2021
Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments limited by toxicity. The HOPE trial (Harnessing Organoids PErsonalized Therapy) was pilot feasibility aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC test their drug sensitivity correlation clinical outcomes. Experimental Design: PDOs were established heterogeneous...
Background Tumor-specific cytotoxic T cells and cell receptors are effective tools for cancer immunotherapy. Most efforts to identify them rely on known antigens or lymphocytes that have infiltrated into the tumor bed. Approaches empirically tumor-targeting by exploiting all expressed surfaces not well developed most carcinomas, including pancreatic cancer. Methods Autologous organoids were stimulated with from patients’ peripheral blood 2 weeks generate organoid-primed (opT) cells. opT...
Background: Given the potential positive and negative impacts of cannabis use during cancer care, more information is needed to understand how changes in legalization social norms have affected clinical disclosure among survivors.Objectives: The purpose this research was explore behaviors, disclosure, needs survivors.Methods: study team conducted cross- sectional analyses using descriptive statistics assess data collected via an online survey distributed through health communities.Findings:...
Abstract The HOPE trial (Harnessing Organoids for PErsonalized Therapy) was a pilot study to test the feasibility of generating patient derived organoids (PDOs) from patients with pancreatic cancer under real world conditions, drug sensitivity against these PDOs, and correlate findings clinical outcomes. Biopsies were obtained primarily during routine care surgical specimens, ascites, fine needle biopsies (FNB) primary tumors, IR guided core liver lymph node metastases. PDOs grown in WNT...
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
<div>AbstractPurpose:<p>Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments limited by toxicity. The HOPE trial (Harnessing Organoids PErsonalized Therapy) was pilot feasibility aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC test their drug sensitivity correlation clinical outcomes.</p>Experimental Design:<p>PDOs were...
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
<div>AbstractPurpose:<p>Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments limited by toxicity. The HOPE trial (Harnessing Organoids PErsonalized Therapy) was pilot feasibility aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC test their drug sensitivity correlation clinical outcomes.</p>Experimental Design:<p>PDOs were...
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients Pancreatic Cancer
Abstract Tumor-specific cytotoxic T cells are effective tools for cancer immunotherapy, but the ability to generate them continues be a challenge. Furthermore, there no compelling approaches empirically identify tumor-targeting and cell receptors by exploiting multitude of antigens on tumor surfaces. Here, we use patients’ peripheral blood autologous organoids enrich tumor-specific with patient-specific killing mechanisms tissue-resident memory phenotype. We further demonstrate that these...